New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy.
作者信息
Anand Anil C, Acharya Subrat K
机构信息
Department of Gastroenterology & Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar 751024, India.
Fortis Escorts Liver & Digestive Diseases Institute, New Delhi 110025, India.
出版信息
J Clin Exp Hepatol. 2021 May-Jun;11(3):284-287. doi: 10.1016/j.jceh.2021.04.003. Epub 2021 Apr 27.
Abstract
摘要
相似文献
1
New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy.肝细胞癌治疗的新进展：辅助化疗和新辅助化疗的概念
J Clin Exp Hepatol. 2021 May-Jun;11(3):284-287. doi: 10.1016/j.jceh.2021.04.003. Epub 2021 Apr 27.
2
Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation.在等待肝移植的肝细胞癌患者中，射频和微波消融联合经动脉化疗栓塞诱导出等效的组织病理学凝固性坏死。
Hepatobiliary Surg Nutr. 2016 Jun;5(3):225-33. doi: 10.21037/hbsn.2016.01.05.
3
Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chembolization for the Treatment of Hepatocellular Carcinoma.新辅助经动脉单纯化疗栓塞和药物洗脱微球化疗栓塞治疗肝细胞癌后射频消融与微波消融的比较
Curr Probl Diagn Radiol. 2017 Nov-Dec;46(6):402-409. doi: 10.1067/j.cpradiol.2017.02.006. Epub 2017 Feb 20.
4
The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma.经动脉化疗栓塞联合射频消融或微波消融治疗肝细胞癌。
Anal Cell Pathol (Amst). 2019 Aug 26;2019:8619096. doi: 10.1155/2019/8619096. eCollection 2019.
5
Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.联合射频消融或微波消融与经动脉化疗栓塞治疗中期肝细胞癌可提高疗效而不增加并发症：系统评价和荟萃分析。
Int J Hyperthermia. 2022;39(1):455-465. doi: 10.1080/02656736.2022.2048095.
6
Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone.射频消融或微波消融联合经导管动脉化疗栓塞与单纯射频消融治疗肝细胞癌的比较。
Chin J Cancer Res. 2014 Feb;26(1):112-8. doi: 10.3978/j.issn.1000-9604.2014.02.09.
7
Comparison of combined transarterial chemoembolization and ablations in patients with hepatocellular carcinoma: a systematic review and meta-analysis.联合经动脉化疗栓塞和消融治疗肝细胞癌患者的比较：系统评价和荟萃分析。
Abdom Radiol (NY). 2022 Mar;47(3):1009-1023. doi: 10.1007/s00261-021-03368-2. Epub 2022 Jan 4.
8
Current status of the combination therapy of transarterial chemoembolization and local ablation for hepatocellular carcinoma.经导管肝动脉化疗栓塞术联合局部消融治疗肝细胞癌的现状。
Abdom Radiol (NY). 2019 Jun;44(6):2268-2275. doi: 10.1007/s00261-019-01943-2.
9
Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.索拉非尼不耐受的肝细胞癌患者行微波消融和同步经肝动脉化疗栓塞联合 PD-1 抑制剂治疗。
Front Immunol. 2023 Jan 10;13:1097625. doi: 10.3389/fimmu.2022.1097625. eCollection 2022.
10
Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma.经动脉化疗栓塞联合射频或微波消融治疗肝细胞癌
Asian Pac J Cancer Prev. 2017 Jan 1;18(1):189-194. doi: 10.22034/APJCP.2017.18.1.189.
引用本文的文献
1
FCGR2A contributes to M2 macrophages polarization in HCC through IL-4/JAK/STAT6 axis.FCGR2A通过IL-4/JAK/STAT6轴促进肝癌中M2巨噬细胞极化。
Transl Oncol. 2025 Aug;58:102429. doi: 10.1016/j.tranon.2025.102429. Epub 2025 Jun 6.
2
Local-region treatment comparison following conversion therapy of hepatocellular carcinoma: a period and age-dependent analysis.肝细胞癌转化治疗后的局部区域治疗比较：一项基于时期和年龄的分析。
Ther Adv Med Oncol. 2025 Mar 19;17:17588359251316665. doi: 10.1177/17588359251316665. eCollection 2025.
3
Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis.门静脉血栓形成的肝细胞癌新辅助治疗的疗效与安全性：一项荟萃分析。
Oncol Lett. 2025 Jan 7;29(3):122. doi: 10.3892/ol.2025.14868. eCollection 2025 Mar.
4
2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations.印度国家肝脏研究协会关于中晚期肝细胞癌管理共识的2023年更新：普里III建议
J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101269. doi: 10.1016/j.jceh.2023.08.005. Epub 2023 Aug 19.
5
Hepatocellular Carcinoma: Surveillance, Diagnosis, Evaluation and Management.肝细胞癌：监测、诊断、评估与管理
Cancers (Basel). 2023 Oct 24;15(21):5118. doi: 10.3390/cancers15215118.
6
Ephrin-A4 Ligand (EFNA4) Predicts Poor Prognosis of Hepatocellular Carcinoma and Promotes Tumor Proliferation.埃菲林-A4配体（EFNA4）预示肝细胞癌预后不良并促进肿瘤增殖。
J Clin Exp Hepatol. 2023 Sep-Oct;13(5):767-773. doi: 10.1016/j.jceh.2023.04.004. Epub 2023 Apr 15.
7
Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions.印度肝细胞癌的全面综述：当前挑战与未来方向。
JCO Glob Oncol. 2022 Oct;8:e2200118. doi: 10.1200/GO.22.00118.
8
Treatment for Hepatocellular Carcinoma in South Asia.南亚肝细胞癌的治疗
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):641-645. doi: 10.1016/j.jceh.2021.09.018. Epub 2021 Sep 24.
本文引用的文献
1
Percutaneous Cryoablation of Liver Tumors: Initial Experience from a Tertiary Care Center in India.经皮冷冻消融治疗肝脏肿瘤：印度一家三级医疗中心的初步经验。
J Clin Exp Hepatol. 2021 May-Jun;11(3):305-311. doi: 10.1016/j.jceh.2020.10.005. Epub 2020 Oct 19.
2
Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience.N-乙酰半胱氨酸在肝细胞癌经动脉化疗栓塞术后转氨酶升高中的作用：单中心经验
J Clin Exp Hepatol. 2021 May-Jun;11(3):299-304. doi: 10.1016/j.jceh.2020.10.007. Epub 2020 Oct 27.
3
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.老龄化社会中肝细胞癌全身治疗的最新进展：2020年更新
Liver Cancer. 2020 Dec;9(6):640-662. doi: 10.1159/000511001. Epub 2020 Nov 17.
4
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.肝细胞癌免疫治疗新辅助应用的前景
Hepatology. 2021 Jul;74(1):483-490. doi: 10.1002/hep.31697. Epub 2021 Jun 28.
5
Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition.局部区域治疗与免疫检查点抑制联合应用的现状。
J Vasc Interv Radiol. 2020 Nov;31(11):1740-1744.e9. doi: 10.1016/j.jvir.2020.07.011. Epub 2020 Oct 2.
6
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.可切除局部晚期、人乳头瘤病毒无关的头颈部癌新辅助和辅助帕博利珠单抗治疗：一项多中心、Ⅱ期试验。
Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695. Epub 2020 Jul 14.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌患者新辅助阿替利珠单抗和化疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
9
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.印度肝脏研究全国协会关于印度肝细胞癌预防、诊断和管理的共识2019年更新：普里II建议
J Clin Exp Hepatol. 2020 Jan-Feb;10(1):43-80. doi: 10.1016/j.jceh.2019.09.007. Epub 2019 Sep 23.
10
Role of locoregional therapies in the wake of systemic therapy.全身治疗后的局部区域治疗的作用。
J Hepatol. 2020 Feb;72(2):277-287. doi: 10.1016/j.jhep.2019.09.023.
Zotero 插件